MedPath

Agonist Gonadotropin-Releasing Hormone (GnRH) Versus Antagonist GnRH

Phase 3
Conditions
Infertility
Interventions
Registration Number
NCT00823602
Lead Sponsor
Yazd Research & Clinical Center for Infertility
Brief Summary

Literature suggests that GnRH antagonists are comparatively more often used in cycles which have an unfavorable prior prognosis, and this protocol is an ideal one for poor responder patients. Up to now, however not enough prospectives have been published to prove any beneficial effect of antagonists on the first cycle assisted reproductive technique.

This prospective study will do to evaluate the efficacy of gonadotropin releasing hormone antagonist in comparison with the standard long protocol in the first cycle of ART.

The investigators will randomize 160 patients undergoing ART for the first time . Group 1 (n=80) was stimulate with a standard long protocol and group 2 (n=80) stimulated with GnRH antagonist and then result of ART compare in two group .

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
Female
Target Recruitment
2
Inclusion Criteria
  • first cycle of ART
  • age < 35 years
  • basal FSH < 10 IU/L
Exclusion Criteria
  • previous IVF or ICSI, hyperprolactinemia, hyperthyroidism, hypothyroidism, uterine abnormality, severe endometriosis
  • only one ovary

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
1ganirelixGnRH antagonist "ganirelix" 0.25 mg fromm 6th ovarian stimulation
2suprefactGnRH agonist, suprefact, stimulation with a standard long protocol
Primary Outcome Measures
NameTimeMethod
pregnancy rate2weeks
Secondary Outcome Measures
NameTimeMethod
ovarian stimulation10days

Trial Locations

Locations (1)

Yazd Research and Clinical Center For Infertility

🇮🇷

Yazd, Iran, Islamic Republic of

© Copyright 2025. All Rights Reserved by MedPath